セラノスティクスの世界市場予測(~2028):製品別、用途別

■ 英語タイトル:Theranostics Market by Product (Diagnostic imaging (PET, CT, MRI), Radiopharmaceuticals (Lu-177, Sm-153, Ra-223, I-131), Biomarker screening, Software), Application (Prostate Cancer, Bone metastasis), & Stakeholder Expectations - Global Forecast to 2028

調査会社MarketsandMarkets社が発行したリサーチレポート(データ管理コード:PH8913-24)■ 発行会社/調査会社:MarketsandMarkets
■ 商品コード:PH8913-24
■ 発行日:2024年1月30日
■ 調査対象地域:グローバル
■ 産業分野:医療
■ ページ数:194
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後24時間以内)
■ 販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥984,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥1,206,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[セラノスティクスの世界市場予測(~2028):製品別、用途別]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

“世界のセラノスティクス市場は、2023年の21億米ドルから2028年には43億米ドルに達すると予測され、2023年から2028年までの年平均成長率は15.5%”ベビーブーマー人口の増加や放射性医薬品の研究開発の進歩などの要因が、この市場の成長を高めています。研究開発活動の増加、臨床試験数の増加、政府の取り組みがセラノスティクス市場の成長に寄与しています。

“放射性医薬品セグメントが2022年の市場で最大シェアを占める”
製品別に見ると、セラノスティクス市場は画像診断、放射性医薬品、IVD/バイオマーカースクリーニング、ソフトウェアおよびサービスに区分されます。2022年に最大の市場シェアを占めるのは放射性医薬品セグメントでした。このセグメントの大きなシェアは、セラノスティクスの採用が増加していることと、癌などの慢性疾患の有病率が増加していることに起因しています。

“前立腺がんアプリケーションセグメントは、予測期間中、アプリケーション別セラノスティクス市場で最も高いCAGRを記録すると予測”
用途に基づき、セラノスティクス市場は前立腺がん、骨転移、その他のがん、その他の用途に区分されます。前立腺がんアプリケーション分野は、2023年から2028年にかけて、セラノスティクス市場で最も高いCAGRを記録すると予測されています。がん人口の増加や、他の用途におけるセラノスティクスの利点を知るための進行中の臨床試験などの要因が、市場の成長を促進しています。

“アジア太平洋の市場が予測期間中に最も高い成長を目撃する見込み”
アジア太平洋のセラノスティクス市場は、予測期間中に最も高いCAGRを記録する見込みですが、その主な理由は、同地域における医療インフラの進化と大手企業の注力度の高まりです。中国やインドなどの新興国における医療インフラは急速なペースで進化しており、病院やその他のエンドユーザーによる大規模な投資に繋がっています。これらの要因は、この地域におけるセラノスティクス市場の成長を促進すると予想されます。

本レポートで参照した主要参入企業の内訳は以下の通りです:

- 企業タイプ別 ティア1:48%、ティア2:36%、ティア3:16%
- 役職別 ディレクターレベル:14%、Cレベル:10%、その他:76%
- 地域別 北米:40%、ヨーロッパ:32%、アジア太平洋地:20%、その他地域:8%

セラノスティクス市場の有力企業には、Advanced Accelerator Applications (France), Bayer AG (Germany), GE Healthcare (US)などが挙げられます。

調査範囲

本レポートでは、製品、用途、エンドユーザー、地域に基づいてセラノスティクス市場を調査しています。また、市場成長に影響を与える要因を網羅し、市場における様々な機会と課題を分析し、市場リーダーのための競争環境の詳細を提供します。さらに、微小市場の成長動向を分析し、3つの主要地域(およびこれらの地域のそれぞれの国)に関して市場セグメントの収益を予測しています。

レポート購入の理由

本レポートは、セラノスティクス市場全体とサブセグメントに関する収益数字の最も近い近似値に関する情報を提供することで、市場リーダー/新規参入者に役立ちます。本レポートは、利害関係者が競争状況を理解し、より多くの洞察を得ることで、事業の位置づけを高め、適切な市場参入戦略を計画するのに役立ちます。また、本レポートは、関係者が市場の脈動を理解し、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供するのに役立ちます。

本レポートは、以下のポイントに関する洞察を提供します:

- セラノスティクス市場の成長に影響を与える主な促進要因(老年人口の増加と関連疾患の有病率の上昇、放射性医薬品の使用増加、精密医療への注目の高まり)、阻害要因(放射性医薬品の寿命の短さ、不利な償還シナリオ)、機会(新興国における成長機会、放射性医薬品の研究開発の進展)、課題(病院予算の削減と設備コストの高さ)の分析しました。
- 製品開発/イノベーション: セラノスティクス市場における今後の技術、研究開発活動、新製品・新サービスの発売に関する詳細な洞察を提供します。
- 市場開発: 有利な市場に関する包括的情報-当レポートでは、さまざまな地域のセラノスティクス市場を分析しています。
- 市場の多様化: 新製品&サービス、未開拓の地域、最近の開発、セラノスティックス市場における投資に関する詳細情報を記載しています。
- 競争力の評価: Advanced Accelerator Applications社(フランス)、Bayer AG社(ドイツ)、GE Healthcare社(アメリカ)などの主要企業の市場シェア、成長戦略、サービス内容を詳細に評価しています。

1. 序論
2. 調査方法
3. エグゼクティブサマリー
4. プレミアムインサイト
5. 市場概要
6. 世界のセラノスティクス市場規模:製品別
7. 世界のセラノスティクス市場規模:用途別
8. 世界のセラノスティクス市場規模:エンドユーザー別
9. 世界のセラノスティクス市場規模:地域別
10. 競争状況
11. 企業情報
12. 付録

*** レポート目次(コンテンツ)***

1 INTRODUCTION 22
1.1 STUDY OBJECTIVES 22
1.2 MARKET DEFINITION 22
1.3 INCLUSIONS & EXCLUSIONS 22
1.4 MARKET SEGMENTATION 23
1.4.1 MARKETS COVERED 23
1.4.2 REGIONS COVERED 23
1.4.3 YEARS CONSIDERED 24
1.4.4 CURRENCY CONSIDERED 24
1.5 RESEARCH LIMITATIONS 24
1.6 STAKEHOLDERS 25
1.7 RECESSION IMPACT: THERANOSTICS MARKET 25
2 RESEARCH METHODOLOGY 26
2.1 RESEARCH DATA 26
FIGURE 1 RESEARCH DESIGN METHODOLOGY 26
2.1.1 SECONDARY DATA 27
2.1.2 PRIMARY DATA 28
2.1.2.1 Primary sources 28
2.1.2.2 Key industry insights 29
2.1.2.3 Breakdown of primaries 29
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 29
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 30
2.2 MARKET SIZE ESTIMATION 30
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 31
2.2.1 BOTTOM-UP APPROACH 31
2.2.1.1 Approach 1: Company revenue estimation approach 32
FIGURE 5 COMPANY REVENUE ESTIMATION 32
FIGURE 6 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF BAYER AG 33
2.2.1.2 Approach 2: Patient population-based market estimation 33
FIGURE 7 BOTTOM-UP APPROACH: THERANOSTICS MARKET 34
2.2.1.3 Growth forecast 34
2.2.1.4 CAGR projections 35
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 35
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 35
FIGURE 9 DATA TRIANGULATION METHODOLOGY 36
2.3.1 MARKET SHARE ESTIMATION 36
2.4 STUDY ASSUMPTIONS 37
2.4.1 MARKET ASSUMPTIONS 37
2.4.2 GROWTH RATE ASSUMPTIONS 37
2.5 RISK ASSESSMENT 38
TABLE 1 RISK ASSESSMENT: THERANOSTICS MARKET 38
2.6 IMPACT OF ECONOMIC RECESSION ON THERANOSTICS MARKET 38
3 EXECUTIVE SUMMARY 39
FIGURE 10 THERANOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 39
FIGURE 11 THERANOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 40
FIGURE 12 THERANOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 40
FIGURE 13 REGIONAL SNAPSHOT OF THERANOSTICS MARKET 41
4 PREMIUM INSIGHTS 42
4.1 THERANOSTICS MARKET OVERVIEW 42
FIGURE 14 RISING PREVALENCE OF CANCER AND GROWING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET 42
4.2 NORTH AMERICA: THERANOSTICS MARKET, BY PRODUCT (USD MILLION) 43
FIGURE 15 RADIOPHARMACEUTICALS TO COMMAND LARGEST MARKET SHARE IN NORTH AMERICAN THERANOSTICS MARKET DURING FORECAST PERIOD 43
4.3 EUROPE: THERANOSTICS MARKET, BY APPLICATION (USD MILLION) 44
FIGURE 16 PROSTATE CANCER TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD 44
4.4 ASIA PACIFIC: THERANOSTICS MARKET, BY END USER (USD MILLION) 44
FIGURE 17 HOSPITALS AND CANCER CARE CENTERS TO COMMAND LARGEST SHARE IN ASIA PACIFIC MARKET DURING FORECAST PERIOD 44
4.5 GEOGRAPHIC SNAPSHOT: THERANOSTICS MARKET 45
FIGURE 18 CHINA TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD 45
5 MARKET OVERVIEW 46
5.1 INTRODUCTION 46
5.2 MARKET DYNAMICS 46
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: THERANOSTICS MARKET 46
5.2.1 DRIVERS 47
5.2.1.1 Growing geriatric population and rising prevalence of target diseases 47
5.2.1.2 Increasing use of radiopharmaceuticals in neurological applications 47
5.2.1.3 Growing focus on precision medicine 47
5.2.2 RESTRAINTS 48
5.2.2.1 Short half-life of radiopharmaceuticals 48
TABLE 2 PHYSICAL HALF-LIFE OF RADIOPHARMACEUTICALS 48
5.2.2.2 Unfavorable healthcare reimbursement scenario 49
5.2.3 OPPORTUNITIES 49
5.2.3.1 Growth opportunities in emerging economies 49
5.2.3.2 Rising number of R&D programs for radiopharmaceuticals 49
5.2.4 CHALLENGES 50
5.2.4.1 Hospital budget cuts and high equipment costs 50
5.3 PRICING ANALYSIS 50
FIGURE 20 AVERAGE SELLING PRICE FOR RADIOPHARMACEUTICALS 51
TABLE 3 AVERAGE COST FOR THERANOSTICS TREATMENT, BY REGION 52
5.4 VALUE CHAIN ANALYSIS 52
FIGURE 21 VALUE CHAIN ANALYSIS: THERANOSTICS MARKET 52
5.5 ECOSYSTEM/MARKET MAP 53
5.6 SUPPLY CHAIN ANALYSIS 53
5.6.1 PROMINENT COMPANIES 53
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 54
5.6.3 END USERS 54
FIGURE 22 SUPPLY CHAIN ANALYSIS: THERANOSTICS MARKET 54
5.7 PORTER’S FIVE FORCES ANALYSIS 54
TABLE 4 PORTER’S FIVE FORCES ANALYSIS: THERANOSTICS MARKET 55
5.7.1 INTENSITY OF COMPETITIVE RIVALRY 55
5.7.2 BARGAINING POWER OF SUPPLIERS 55
5.7.3 BARGAINING POWER OF BUYERS 55
5.7.4 THREAT OF SUBSTITUTES 56
5.7.5 THREAT OF NEW ENTRANTS 56
5.8 REGULATORY LANDSCAPE 56
5.8.1 NORTH AMERICA 56
5.8.1.1 US 56
5.8.1.2 Canada 56
5.8.2 EUROPE 57
5.8.3 ASIA PACIFIC 57
5.8.3.1 Australia 57
5.8.3.2 India 57
5.8.3.3 China 58
5.8.4 REST OF THE WORLD 58
5.8.4.1 Turkey 58
5.8.4.2 UAE 58
5.8.4.3 South Africa 58
TABLE 5 REGULATORY AGENCIES AND GUIDELINES 59
5.9 TIMELINE FOR THERANOSTICS MARKET 61
5.10 REIMBURSEMENT ANALYSIS 61
TABLE 6 MEDICAL REIMBURSEMENT CODES FOR THERANOSTICS IN US, 2022 62
5.11 TRADE ANALYSIS 62
5.11.1 TRADE ANALYSIS FOR THERANOSTICS MARKET 62
TABLE 7 IMPORT DATA FOR RADIOPHARMACEUTICALS, BY COUNTRY, 2018–2022 (USD THOUSAND) 62
TABLE 8 EXPORT DATA FOR RADIOPHARMACEUTICALS, BY COUNTRY, 2018–2022 (USD THOUSAND) 63
5.12 PATENT ANALYSIS 64
FIGURE 23 TOP 10 PATENT APPLICANTS FOR THERANOSTICS (JANUARY 2012–DECEMBER 2022) 64
5.13 CASE STUDY ANALYSIS 65
TABLE 9 CASE STUDY 1: LUTETIUM-177-PSMA-617 FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER 65
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 65
5.14.1 KEY STAKEHOLDERS 65
TABLE 10 KEY STAKEHOLDERS AND THEIR REQUIREMENTS 65
5.14.2 IMPACT ANALYSIS OF KEY BUYING CRITERIA 66
TABLE 11 IMPACT OF KEY STAKEHOLDERS ON BUYING CRITERIA 66
5.15 KEY CONFERENCES & EVENTS 69
TABLE 12 LIST OF KEY CONFERENCES & EVENTS, 2023–2024 69
5.16 CLINICAL RESEARCH DATA FOR THERANOSTICS MARKET 70
6 THERANOSTICS MARKET, BY PRODUCT 73
6.1 INTRODUCTION 74
TABLE 13 THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 74
6.2 DIAGNOSTIC IMAGING 74
6.2.1 EASY ANALYSIS OF DISEASE CONDITIONS AND ACCURATE THERAPIES TO DRIVE MARKET 74
TABLE 14 THERANOSTICS MARKET FOR DIAGNOSTIC IMAGING, BY REGION, 2021–2028 (USD MILLION) 75
6.3 RADIOPHARMACEUTICALS 75
TABLE 15 THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 75
TABLE 16 THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY REGION, 2021–2028 (USD MILLION) 76
6.3.1 LUTETIUM-177 76
6.3.1.1 Increasing incidence of neuroendocrine cancer to boost segment 76
TABLE 17 LUTETIUM-177 MARKET, BY REGION, 2021–2028 (USD MILLION) 77
6.3.1.2 Samarium-153 77
6.3.1.3 Rising incidence of bone metastasis to drive segment growth 77
TABLE 18 SAMARIUM-153 MARKET, BY REGION, 2021–2028 (USD MILLION) 77
6.3.1.4 Radium-223 78
6.3.1.4.1 Easy production of Radium-223 molecule to support market growth 78
TABLE 19 RADIUM-223 MARKET, BY REGION, 2021–2028 (USD MILLION) 78
6.3.1.5 Iodine-131 78
6.3.1.5.1 Increased applications in thyroid cancer and hyperthyroidism treatment to propel market 78

TABLE 20 IODINE-131 MARKET, BY REGION, 2021–2028 (USD MILLION) 79
6.3.1.6 Yttrium-90 79
6.3.1.6.1 Rising use in non-Hodgkin lymphoma and oncology radiotheranostics to drive segment 79
TABLE 21 YTTRIUM-90 MARKET, BY REGION, 2021–2028 (USD MILLION) 79
6.3.1.7 Other radiopharmaceuticals 80
TABLE 22 OTHER RADIOPHARMACEUTICALS MARKET, BY REGION, 2021–2028 (USD MILLION) 80
6.4 IVD/BIOMARKER SCREENING 80
6.4.1 RISING ADOPTION OF THERANOSTICS TREATMENT TO SUPPORT MARKET GROWTH 80
TABLE 23 THERANOSTICS MARKET FOR IVD/BIOMARKER SCREENING, BY REGION, 2021–2028 (USD MILLION) 81
6.5 SOFTWARE & SERVICES 81
6.5.1 RISING USE OF NOVEL SOFTWARE AND INCREASING DEMAND FOR IMAGING SERVICES TO PROPEL MARKET 81
TABLE 24 THERANOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION) 82
7 THERANOSTICS MARKET, BY APPLICATION 83
7.1 INTRODUCTION 84
TABLE 25 THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 84
7.2 PROSTATE CANCER 84
7.2.1 RISING INCIDENCE OF PROSTATE CANCER AMONG MEN TO FUEL MARKET 84
TABLE 26 THERANOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION) 85
7.3 BONE METASTASIS 85
7.3.1 INTRODUCTION OF NOVEL MEDICAL THERAPIES TO DRIVE MARKET 85
TABLE 27 THERANOSTICS MARKET FOR BONE METASTASIS, BY REGION, 2021–2028 (USD MILLION) 86
7.4 OTHER CANCERS 86
TABLE 28 THERANOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION) 86
7.5 OTHER APPLICATIONS 87
TABLE 29 THERANOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 87
8 THERANOSTICS MARKET, BY END USER 88
8.1 INTRODUCTION 89
TABLE 30 THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 89
8.2 HOSPITALS AND CANCER CARE CENTERS 89
8.2.1 RISING TREND OF MODERNIZING IMAGING WORKFLOW SYSTEMS TO DRIVE MARKET 89
TABLE 31 THERANOSTICS MARKET FOR HOSPITALS AND CANCER CARE CENTERS, BY REGION, 2021–2028 (USD MILLION) 90

8.3 THERANOSTICS CENTERS 91
8.3.1 GROWING FOCUS ON TARGETED THERAPIES AND RISING PREVALENCE OF CHRONIC DISEASES TO PROPEL MARKET 91
TABLE 32 THERANOSTICS MARKET FOR THERANOSTICS CENTERS, BY REGION, 2021–2028 (USD MILLION) 91
8.4 RESEARCH AND ACADEMIC CENTERS 92
8.4.1 INCREASING COLLABORATIONS BETWEEN THERANOSTICS COMPANIES AND ACADEMIA TO SUPPORT MARKET GROWTH 92
TABLE 33 THERANOSTICS MARKET FOR RESEARCH AND ACADEMIC CENTERS, BY REGION, 2021–2028 (USD MILLION) 92
9 THERANOSTICS MARKET, BY REGION 93
9.1 INTRODUCTION 94
TABLE 34 THERANOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION) 94
9.2 NORTH AMERICA 94
FIGURE 24 NORTH AMERICA: CANCER PREVALENCE, 2012–2020 95
FIGURE 25 NORTH AMERICA: THERANOSTICS MARKET SNAPSHOT (2022) 96
TABLE 35 NORTH AMERICA: THERANOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 36 NORTH AMERICA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 97
TABLE 37 NORTH AMERICA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 97
TABLE 38 NORTH AMERICA: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 98
TABLE 39 NORTH AMERICA: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 98
9.3 NORTH AMERICA: RECESSION IMPACT 98
9.3.1 US 99
9.3.1.1 US to dominate North American theranostics market during forecast period 99
TABLE 40 US: KEY MACROINDICATORS 99
TABLE 41 US: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 100
TABLE 42 US: THERANOSTICS MARKET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 100
9.3.2 CANADA 101
9.3.2.1 Rising geriatric population and increasing number of initiatives for medical isotope development to drive market 101
TABLE 43 CANADA: KEY MACROINDICATORS 101
TABLE 44 CANADA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 102
TABLE 45 CANADA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 102
9.4 EUROPE 102
TABLE 46 EUROPE: THERANOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 47 EUROPE: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 103
TABLE 48 EUROPE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 104
TABLE 49 EUROPE: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 104
TABLE 50 EUROPE: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 104
9.4.1 EUROPE: RECESSION IMPACT 105
9.4.2 GERMANY 105
9.4.2.1 Well-established healthcare system and increased geriatric population to drive market 105
TABLE 51 GERMANY: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 106
TABLE 52 GERMANY: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 106
9.4.3 UK 107
9.4.3.1 Increasing government funding in diagnostic imaging to support market growth 107
TABLE 53 UK: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 108
TABLE 54 UK: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 108
9.4.4 FRANCE 108
9.4.4.1 Favorable government initiatives and high incidence of cancer to propel market 108
TABLE 55 FRANCE: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 109
TABLE 56 FRANCE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 110
9.4.5 REST OF EUROPE 110
TABLE 57 REST OF EUROPE: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 111
TABLE 58 REST OF EUROPE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 111
9.5 ASIA PACIFIC 112
FIGURE 26 ASIA PACIFIC: CANCER PREVALENCE, 2012–2020 112
FIGURE 27 ASIA PACIFIC: THERANOSTICS MARKET SNAPSHOT (2022) 113
TABLE 59 ASIA PACIFIC: THERANOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 60 ASIA PACIFIC: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 114
TABLE 61 ASIA PACIFIC: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 62 ASIA PACIFIC: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 115
TABLE 63 ASIA PACIFIC: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 116
9.5.1 ASIA PACIFIC: RECESSION IMPACT 116
9.5.2 JAPAN 116
9.5.2.1 Established nuclear medicine infrastructure and better accessibility of healthcare services to drive market 116
TABLE 64 JAPAN: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 117
TABLE 65 JAPAN: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 118
9.5.3 CHINA 118
9.5.3.1 Increasing number of government initiatives and growing geriatric population to drive market 118
TABLE 66 CHINA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 119
TABLE 67 CHINA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 119
9.5.4 INDIA 120
9.5.4.1 Rising number of nuclear medicine facilities and increasing incidence of chronic diseases to propel market 120
TABLE 68 INDIA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 121
TABLE 69 INDIA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 121
9.5.5 REST OF ASIA PACIFIC 121
TABLE 70 REST OF ASIA PACIFIC: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 122
TABLE 71 REST OF ASIA PACIFIC: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 123
9.6 REST OF THE WORLD 123
TABLE 72 REST OF THE WORLD: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 125
TABLE 73 REST OF THE WORLD: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 74 REST OF THE WORLD: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 126
TABLE 75 REST OF THE WORLD: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 126
9.6.1 REST OF THE WORLD: RECESSION IMPACT 126
10 COMPETITIVE LANDSCAPE 128
10.1 OVERVIEW 128
10.2 KEY STRATEGIES/RIGHT TO WIN 128
10.3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN THERANOSTICS MARKET 129
FIGURE 28 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN THERANOSTICS MARKET 129
10.4 REVENUE SHARE ANALYSIS 130
FIGURE 29 REVENUE SHARE ANALYSIS OF TOP THREE PLAYERS, 2020–2022 130
10.5 MARKET SHARE ANALYSIS 130
FIGURE 30 ADVANCED ACCELERATOR APPLICATIONS COMMANDED LARGEST MARKET SHARE IN 2022 130
TABLE 76 DEGREE OF COMPETITION IN THERANOSTICS MARKET 131
10.6 COMPANY EVALUATION MATRIX 132
10.6.1 STARS 132
10.6.2 EMERGING LEADERS 132
10.6.3 PERVASIVE PLAYERS 132
10.6.4 PARTICIPANTS 132
FIGURE 31 COMPANY EVALUATION MATRIX, 2022 133
10.6.5 COMPANY FOOTPRINT 134
TABLE 77 PRODUCT AND REGIONAL FOOTPRINT 134
10.7 START-UP/SME EVALUATION MATRIX 134
10.7.1 PROGRESSIVE COMPANIES 134
10.7.2 RESPONSIVE COMPANIES 134
10.7.3 DYNAMIC COMPANIES 135
10.7.4 STARTING BLOCKS 135
FIGURE 32 START-UP/SME EVALUATION MATRIX, 2022 135
10.7.5 COMPETITIVE BENCHMARKING 136
TABLE 78 DETAILED LIST OF KEY START-UPS/SMES 136
10.8 COMPETITIVE SCENARIOS & TRENDS 136
11 COMPANY PROFILES 139
11.1 KEY PLAYERS 139
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 ADVANCED ACCELERATOR APPLICATIONS 139
TABLE 81 ADVANCED ACCELERATOR APPLICATIONS: COMPANY OVERVIEW 139
11.1.2 BAYER AG 142
TABLE 82 BAYER AG: COMPANY OVERVIEW 142
FIGURE 33 BAYER AG: COMPANY SNAPSHOT (2022) 142
11.1.3 GE HEALTHCARE 145
TABLE 83 GE HEALTHCARE: COMPANY OVERVIEW 145
FIGURE 34 GE HEALTHCARE: COMPANY SNAPSHOT (2022) 146
11.1.4 SIEMENS HEALTHINEERS AG 150
TABLE 84 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 150
FIGURE 35 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 151
11.1.5 CARDINAL HEALTH 154
TABLE 85 CARDINAL HEALTH: COMPANY OVERVIEW 154
FIGURE 36 CARDINAL HEALTH: COMPANY SNAPSHOT (2022) 155
11.1.6 PHILIPS HEALTHCARE 157
TABLE 86 PHILIPS HEALTHCARE: COMPANY OVERVIEW 157
FIGURE 37 PHILIPS HEALTHCARE: COMPANY SNAPSHOT (2022) 158
11.1.7 CANON INC. 160
TABLE 87 CANON INC.: COMPANY OVERVIEW 160
FIGURE 38 CANON INC.: COMPANY SNAPSHOT (2022) 161
11.1.8 CURIUM 163
TABLE 88 CURIUM: COMPANY OVERVIEW 163
11.1.9 LANTHEUS 166
TABLE 89 LANTHEUS: COMPANY OVERVIEW 166
FIGURE 39 LANTHEUS: COMPANY SNAPSHOT (2022) 166
11.1.10 NORTHSTAR MEDICAL RADIOISOTOPES 168
TABLE 90 NORTHSTAR MEDICAL RADIOISOTOPES: COMPANY OVERVIEW 168
11.1.11 ECKERT & ZIEGLER 171
TABLE 91 ECKERT & ZIEGLER: COMPANY OVERVIEW 171
FIGURE 40 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2022) 171
11.1.12 PHARMALOGIC 174
TABLE 92 PHARMALOGIC: COMPANY OVERVIEW 174
11.1.13 ECZACIBAŞI-MONROL 176
TABLE 93 ECZACIBAŞI-MONROL: COMPANY OVERVIEW 176
11.1.14 ACROTECH BIOPHARMA, INC. 178
TABLE 94 ACROTECH BIOPHARMA, INC.: COMPANY OVERVIEW 178
11.2 OTHER PLAYERS 179
11.2.1 THERMO FISHER SCIENTIFIC INC. 179
11.2.2 GLOBAL MEDICAL SOLUTIONS 180
11.2.3 SHINE TECHNOLOGIES, LLC 181
11.2.4 ISOTOPIA MOLECULAR IMAGING LTD. 182
11.2.5 INSTITUTE OF ISOTOPES 183
11.2.6 CHINA ISOTOPE & RADIATION CORPORATION 184
11.2.7 YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD. 185
11.2.8 ATOMVIE 186
11.2.9 ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH 186
11.2.10 TELIX PHARMACEUTICALS LIMITED 187
11.2.11 BLUE EARTH DIAGNOSTICS 187
11.2.12 SOFIE BIOSCIENCES 188
11.2.13 THERAGNOSTICS 188
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 189
12.1 DISCUSSION GUIDE 189
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 193
12.3 CUSTOMIZATION OPTIONS 195
12.4 RELATED REPORTS 195
12.5 AUTHOR DETAILS 196



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(PH8913-24 )"セラノスティクスの世界市場予測(~2028):製品別、用途別" (英文:Theranostics Market by Product (Diagnostic imaging (PET, CT, MRI), Radiopharmaceuticals (Lu-177, Sm-153, Ra-223, I-131), Biomarker screening, Software), Application (Prostate Cancer, Bone metastasis), & Stakeholder Expectations - Global Forecast to 2028)はMarketsandMarkets社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。